# US 2008/0305102 A1 · Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305102 A1
- Document ID: US20080305102A1
- Status: Published application
- Kind: A1
- Application number: 11/993,774
- Filed: 2006-06-23
- Published: 2008-12-11
- Earliest claimed: 2005-06-23
- Inventors: Toshihiro Nakajima; Yukihiro Kato; Tadayuki Yamadera; Tetsuya Amano
- Web page: https://patentgrep.com/patent/US20080305102A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/1709: {from mammals}
- A61K 38/53: Ligases (6)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/93: {Ligases (6)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A01K 2267/0325: Animal model for autoimmune diseases
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Inhibition of synoviolin function was found to activate the cancer-suppressing protein p53. Substances inhibiting the function of synoviolin are useful as cancer therapeutic agents. The inhibition of synoviolin function was also found to lead to the inhibition of p53 ubiquitination, increased activity of p53 phosphorylation proteins, and the like. Based on these findings, the present invention provides methods capable of efficiently screening for cancer therapeutic agents. Further, it was also found that regulation of the autoubiquitination of synoviolin protein suppresses the proliferation of rheumatoid arthritis synovial cells. Substances regulating the autoubiquitination of synoviolin protein are useful as anti-rheumatic agents. Moreover, the present invention provides methods of efficiently screening for anti-rheumatic agents.

## Claims

### Claim 1

A p53 protein-activating agent, comprising as an active ingredient a substance that inhibits expression and/or function of a synoviolin protein.

### Claim 2 (depends on 1)

The agent of claim 1, wherein the substance that inhibits the expression and/or function is a low molecular weight compound having an activity of inhibiting the binding between a synoviolin protein and a p53 protein.

### Claim 3 (depends on 1)

The agent of claim 1, wherein the substance that inhibits the expression and/or function is a low molecular weight compound having a function of inhibiting ubiquitination of a p53 protein.

### Claim 4 (depends on 1)

The agent of claim 1, wherein the substance that inhibits the expression and/or function is a low molecular weight compound having a function of activating a p53 phosphorylation protein.

### Claim 5 (depends on 4)

The agent of claim 4, wherein the p53 phosphorylation protein is ATM or ATR.

### Claim 6 (depends on 1)

The agent of claim 1, wherein the substance that inhibits the expression and/or function is a compound selected from the group consisting of:
(a) an antisense nucleic acid against a transcript of a synoviolin gene or a portion of the transcript;
(b) a nucleic acid having a ribozyme activity of specifically cleaving a transcript of a synoviolin gene; and
(c) a nucleic acid having an effect of inhibiting the expression of a synoviolin gene by an RNAi effect.

### Claim 7 (depends on 1)

The agent of claim 1, wherein the substance that inhibits the expression and/or function is a compound of (a) or (b):
(a) an antibody which binds to a synoviolin protein and/or a p53 protein; and
(b) a synoviolin protein mutant having a dominant negative property against the synoviolin protein.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A cancer therapeutic agent, comprising the agent for activating a p53 protein of any one of claims 1 to 7 as an active ingredient.

### Claim 9

A method of screening for a cancer therapeutic agent, comprising the steps of:
(a) contacting a test compound with a cell expressing a synoviolin gene;
(b) measuring expression level or activity of a synoviolin protein in the cell; and
(c) selecting a compound that lowers the expression level or activity as compared to when the test compound is not contacted.

### Claim 10

A method of screening for a cancer therapeutic agent, comprising the steps of:
(a) contacting a test compound with a cell or cell extract which contains DNA having a structure in which a transcriptional regulatory region of a synoviolin gene and a reporter gene are operably linked to each other;
(b) measuring the expression level of the reporter gene; and
(c) selecting a compound that lowers the expression level of the reporter gene as compared to when the test compound is not contacted.

### Claim 11

A method of screening for a cancer therapeutic agent, comprising the steps of;
(a) contacting a synoviolin protein, a p53 protein, and a test compound;
(b) measuring the binding activity between the synoviolin protein and the p53 protein; and
(c) selecting a compound that lowers the binding activity as compared to when the test compound is not contacted.

### Claim 12

A method of screening for a cancer therapeutic agent, comprising the steps of:
(a) contacting a synoviolin protein, a p53 protein, and a test compound;
(b) measuring ubiquitination of the p53 protein; and
(c) selecting a compound that lowers the ubiquitination as compared to when the test compound is not contacted.

### Claim 13

A method of screening for a cancer therapeutic agent, comprising the steps of:
(a) contacting a synoviolin protein, a p53 protein, a p53 phosphorylation protein, and a test compound;
(b) measuring phosphorylation activity of the p53 phosphorylation protein which uses the p53 protein as a substrate; and
(c) selecting a compound that increases the phosphorylation activity as compared to when the test compound is not contacted.

### Claim 14 (depends on 13)

The method of claim 13, wherein the p53 phosphorylation protein is ATM or ATR.

### Claim 15

A kit for screening for a cancer therapeutic agent, comprising as components:
a synoviolin protein; and
a p53 protein.

### Claim 16

An anti-rheumatic agent comprising as an active ingredient a substance having a function of regulating autoubiquitination of a synoviolin protein.

### Claim 17 (depends on 16)

The anti-rheumatic agent of claim 16, wherein the substance having a function of regulating the autoubiquitination of a synoviolin protein is a low molecular weight compound.

### Claim 18 (depends on 17)

The anti-rheumatic agent of claim 17, wherein the low molecular weight compound is represented by formula (I) or (II):

### Claim 19 (depends on 18)

The anti-rheumatic agent of claim 18, which has an effect of suppressing proliferation of a rheumatoid arthritis synovial cell.

### Claim 20

A method of screening for an anti-rheumatic agent, comprising the steps of:
(a) contacting a test compound with a cell expressing a synoviolin gene;
(b) measuring expression level or activity of a synoviolin protein in the cell; and
(c) selecting a compound that lowers the expression level or activity as compared to when the test compound is not contacted.

### Claim 21

A method of screening for an anti-rheumatic agent, comprising the steps of:
(a) contacting a test compound with a cell or cell extract which contains DNA having a structure in which a transcriptional regulatory region of a synoviolin gene and a reporter gene are operably linked to each other;
(b) measuring the expression level of the reporter gene; and
(c) selecting a compound that lowers the expression level of the reporter gene as compared to when the test compound is not contacted.

### Claim 22

A method of screening for an anti-rheumatic agent, comprising the steps of:
(a) contacting a synoviolin protein and a test compound;
(b) measuring autoubiquitination of the synoviolin protein; and
(c) selecting a compound regulating the autoubiquitination as compared to when the test compound is not contacted.

### Claim 23

A kit for screening for an anti-rheumatic agent, comprising a synoviolin protein as a component.
